Loading…
BMEA
Biomea Fusion, Inc.
NASDAQ· Healthcare· Biotechnology· CUSIP 09077A106
$1.73+2.98%Price as of Aug 29, 18:31 UTC · updated once a day, after the close
Key metrics
- Market cap
- $125.08M
- P/E
- —
- Forward P/E
- —
- P/B
- 10.4x
- Dividend yield
- —
- Payout
- —
- EPS
- -$0.18
- ROE
- -164.14%
- Profit margin
- 0.00%
- Revenue growth
- —
- Beta
- -0.30
- 52-week high
- $2.99
- 52-week low
- $0.87
History
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Investors holding this
Major managers that reported this stock in their latest 13F.
Price over time
▼ -87.7% over 5Y.
today you would have $110.28▼ -89.0%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Indicators, year by year
The last 5 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Year-end price | $1.24 | $3.88 | $14.52 | $8.43 | $7.45 | |
| P/B | 2.8x | 3.0x | 2.8x | 3.1x | 2.3x | 1.2x |
| EPS | -$1.18 | -$3.83 | -$3.44 | -$2.80 | -$1.74 | |
| ROE | -75.39% | -209.11% | -268.41% | -69.28% | -75.39% | -23.25% |
Others in the same sector
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| CBUSCibus, Inc. | $1.65 | — | 8.5x | — | -223.16% | $126.11M |
| PMNProMIS Neurosciences Inc. | $13.79 | — | 2.5x | — | -172.30% | $123.62M |
| AARDAardvark Therapeutics, Inc. | $5.79 | — | 1.7x | — | -66.02% | $126.71M |
| CPIXCumberland Pharmaceuticals Inc | $8.46 |
About the company
Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It's lead clinical program's drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical trials of icovamenib for the treatment of Type 1 and Type 2 diabetes; COVALENT-211, which is in Phase II clinical trial of icovamenib for treating insulin-deficient type 2 diabetes; and COVALENT-212, which is in Phase II clinical trial of icovamenib for the treatment of type 2 diabetes. The company is also developing BMF-650, which is in Phase I glucagon-like peptide-131 clinical trial for the treatment of obesity. The company was incorporated in 2017 and is headquartered in San Carlos, California.
- 37
- San Carlos, United States
Company description provided by Yahoo Finance.